Systematic review with meta‐analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B
- 1 December 2021
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (1) , 8-25
Abstract
Summary: Background: Although hepatitis B surface antigen (HBsAg) loss is considered the ideal therapeutic endpoint for the treatment of chronic hepatitis B virus (HBV) infection, its impact on clinical outcomes remains uncertain.Aim: To assess the impact of HBsAg loss on clinical outcomes following spontaneous and treatment‐related HBsAg loss.Methods: We searched PUBMED, Embase, the Cochrane library, and published abstracts through to May 2021 for studies that reported HBsAg loss, had >1 year of follow‐up and reported at least one clinical outcome in adults with chronic HBV infection.Results: We identified 57 studies (258 744 HBsAg‐positive patients, 63 270 with HBsAg loss). Based on 24 studies including 160 598 patients with and without HBsAg loss, HBsAg loss was associated with a non‐significant 23% relative risk reduction of developing hepatocellular carcinoma (HCC) compared to those who remained HBsAg‐positive (RR = 0.77; 95% CI: 0.38‐1.57). In subgroup meta‐analysis of 10 studies, treatment‐related HBsAg loss was associated with a non‐significant higher pooled proportion of HCC (0.94%) compared to spontaneous HBsAg loss (0.45%). HCC development after HBsAg loss was significantly higher in males, those with underlying cirrhosis, and those with a family history of HCC. HBsAg loss was associated with lower pooled proportions of incident cirrhosis, hepatic decompensation, overall and liver‐related mortality compared to no HBsAg loss. Substantial heterogeneity was noted across studies for all outcomes.Conclusion: HBsAg loss is associated with a reduced risk of clinical outcomes. However, several shortcomings in the published studies prevent a more definitive conclusion on the potential benefits of HBsAg loss.Keywords
This publication has 62 references indexed in Scilit:
- Family history of liver cancer and hepatocellular carcinomaHepatology, 2011
- Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen–Negative Chronic Hepatitis B PatientsThe Journal of Infectious Diseases, 2011
- HBsAg Seroclearance in Chronic Hepatitis BJournal of Clinical Gastroenterology, 2011
- Identification of androgen response elements in the enhancer I of hepatitis B virus: A mechanism for sex disparity in chronic hepatitis B #Hepatology, 2009
- Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface AntigenClinical Gastroenterology and Hepatology, 2009
- Hepatitis B Virus Infection and Hepatocellular Carcinoma Among Parous Taiwanese Women: Nationwide Cohort StudyJNCI: Journal of the National Cancer Institute, 2009
- The association of family history of liver cancer with hepatocellular carcinoma: A case-control study in the United StatesJournal of Hepatology, 2009
- Androgen Receptor Is a New Potential Therapeutic Target for the Treatment of Hepatocellular CarcinomaGastroenterology, 2008
- Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV InfectionThe Korean Journal of Internal Medicine, 2007
- Long-Term Outcome after Hepatitis B Surface Antigen Seroclearance in Patients with Chronic Hepatitis BThe American Journal of Medicine, 2006